ATLAS fair value
ATLAS has no fair value for this stock today.
Incannex Healthcare stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
Prices as of Oct 27, 2026 · USD
ATLAS has no fair value for this stock today.
47%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Incannex Healthcare a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.34 and $2.90; in 9 out of 10, between $1.93 and $3.51. Estimated annual volatility is 49%.
ATLAS does not publish a fair value for IXHL right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks IXHL has traded between $2.49 and $14.91. Today it is 82.4% below that high and 6% above its low.
Its beta is 2.83: it tends to move more than the market, both up and down.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options.
Want to see everything about Incannex Healthcare?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options.
47%: close to a coin flip. In half of the simulated outcomes, IXHL ends the month between $2.34 and $2.90.
Incannex Healthcare's market capitalization is $40.3M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 49%. In a typical month, half of the outcomes end between $2.34 and $2.90.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy